Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product

Stock Information for Evolus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolus Inc.

Evolus Reports Third Quarter 2025 Financial Results
Evolus to Participate in 2025 Stifel Healthcare Conference
Evolus to Report Third Quarter Financial Results on November 5, 2025
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.